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Abstract: Astaxanthin is a biological antioxidant naturally found in a wide variety of aquatic 
living organisms, and has shown various pharmacological activities, such as anti-inﬂ  ammatory 
and antidiabetic activities. A recent study reported that the administration of astaxanthin induced 
a signiﬁ  cant reduction in blood pressure and delayed the incidence of stroke in stroke-prone 
spontaneously hypertensive rats, suggesting that astaxanthin also has antihypertensive effect. In 
a study using aortic rings of spontaneously hypertensive rats, astaxanthin induced a signiﬁ  cant 
reduction of the contractile responses of the aorta to α-adrenergic receptor agonist and angiotensin 
II, which may contribute to the antihypertensive effect of astaxanthin. In a histopathological study, 
astaxanthin decreased coronary artery wall thickness compared with the control, indicating the 
possibility that astaxanthin ameliorates hypertension-induced vascular remodeling. Astaxanthin 
has anti-inﬂ  ammatory, antidiabetic, antihypertensive, and antioxidative activities; therefore, we 
should perform further studies to elucidate an antiatherogenic effect of astaxanthin.
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Introduction
Astaxanthin, a red-orange carotenoid pigment, is a biological antioxidant that naturally 
found in a wide variety of aquatic living organisms, such as shrimp, crab, and salmon 
(Higuera-Ciapara et al 2006). The green microalgae Haematococcus pluvialis 
and the red yeast Phafﬁ  a rhodozyma are common sources of natural astaxanthin 
(Higuera-Ciapara et al 2006). Astaxanthin has shown various pharmacological 
activities, including anti-inﬂ  ammatory (Kurashige et al 1990; Ohgami et al 2003) and 
antidiabetic activities (Uchiyama et al 2002), as well as antioxidative effects (O’Connor 
et al 1998; Iwamoto et al 2000; Kang et al 2001; Aoi et al 2003). Here, we discuss an 
antihypertensive effect of astaxanthin.
Antihypertensive effects of astaxanthin
Hussein et al (2005) investigated an antihypertensive effect of astaxanthin in spontaneously 
hypertensive rats (SHR), which have been widely used as a model to study the mechanism, 
pathophysiology, and management of hypertension. The administration of astaxanthin 
at the doses of 50 mg/kg for 5 weeks demonstrated a signiﬁ  cant reduction in the systolic 
blood pressure (BP) (−4%) and in the diastolic BP (−10%), and also delayed the incidence 
of stroke in stroke-prone SHR. In the study using aortic rings with intact and denuded 
endothelia, astaxanthin-induced vasodilation by both endothelium-dependent and endo-
thelium-independent manners. They also investigated the effect of astaxanthin on nitric 
oxide (NO), which plays a major role on regulation of vascular tone and arterial blood 
pressure-mediated vasorelaxation. Astaxanthin-mediated vasorelaxation is NO-dependent 
at the lower dose (30 μM), and is NO-independent at the higher dose (100 μM).
The underlying mechanisms for antihypertensive 
effects of astaxanthin
To reveal the underlying mechanisms for antihypertensive effect of astaxanthin, 
Hussein et al (2005) evaluated vascular reactivity of the SHR abdominal aorta, induced Integrated Blood Pressure Control 2008:1  2
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by various substances that modulate vascular tone and 
blood pressure. Astaxanthin induced a signiﬁ  cant reduction 
of the contractile responses of the aortic preparations to 
α-adrenergic receptor agonist, phenylephrine, suggesting that 
astaxanthin may decrease BP by ameliorating the sympathetic 
pathway, especially via α-adrenergic receptor. Astaxanthin 
also demonstrated a signiﬁ  cant reduction of the contractile 
responses to angiotensin II, which has been reported to 
increase superoxide in cultured vascular smooth muscle cells 
(Griendling et al 1994). Superoxide was increased in rats that 
became hypertensive by chronic infusion with angiotensin II 
(Rajagopalan et al 1996). These results indicate that astaxan-
thin-mediated reduction of the contractile responses of aorta 
to angiotensin II may be at least partially due to superoxide 
scavenging effect of astaxanthin.
Astaxanthin has no effect on the endothelium-dependent 
acetylcholine-induced vasodilation; however, it has a 
signiﬁ  cant enhancing effect in the endothelium-independent 
sodium nitroprusside (SNP)-induced vasodilation, 
which challenges previous results. SNP is an endothe-
lium-independent vasorelaxant agent and its effect is 
attributed to its direct effect on vascular smooth muscles. 
However, a recent experiment showed that endothelium 
potentiates the SNP-mediated vasorelaxation, suggesting 
a signiﬁ  cant association between endothelium-mediated 
vasorelaxation and the SNP-mediated vasorelaxation 
(Bonaventura et al 2008). Further investigations should be 
necessary, to elucidate the association between astaxanthin-
mediated vasorelaxation and endothelium-mediated 
vasorelaxation.
Hussein et al (2006) investigated the effect of astaxanthin 
on plasma levels of NO end products nitrite/nitrate 
(NO2
–/NO3
–, termed NOx) in SHR. The synthesis of NO 
by vascular endothelium is responsible for vascular tone 
which plays an essential role in regulation of BP (Rand 
et al 1992). Because NOx are relatively stable in the blood, 
plasma NOx concentration has been reported to be an 
indicator of endogenous NO production (Rhodes et al 1995). 
Oral administration of astaxanthin signiﬁ  cantly reduced 
plasma NOx levels compared with control rats (Hussein 
et al 2006). We should study the inﬂ  uences of astaxanthin 
on NO metabolism including degradation and excretion as 
well as production.
In a histopathological study, astaxanthin decreased 
coronary artery wall thickness compared with the control, and 
signiﬁ  cantly reduced the elastic ﬁ  ber in the aorta, suggesting the 
possibility that astaxanthin ameliorates hypertension-induced 
vascular remodeling (Hussein et al 2006).
Future perspectives
The underlying mechanisms for development of hypertension 
in the metabolic syndrome, which is characterized by 
the simultaneous occurrence of metabolic abnormalities 
including obesity, glucose intolerance, dyslipidemia, 
are very complicated. Sympathetic overactivity, oxidative 
stress, and activated renin-anigiotensin system have 
been suggested to be possible factors for developing 
hypertension in the metabolic syndrome (Yanai et al 
2008). Astaxanthin has a superior antioxidant activity, 
and induces a significant reduction of the contractile 
responses of the aorta to α-adrenergic receptor agonist 
and angiotensin II. Astaxanthin may be effective for the 
management of hypertension in the metabolic syndrome as 
well as essential hypertension.
Astaxanthin has anti-inflammatory, antidiabetic, 
antihypertensive, and antioxidative activities; therefore, we 
should perform further studies to elucidate an antiatherogenic 
effect of astaxanthin.
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